In addition to durvalumab, Celgene has gained another immuno-oncology candidate - BGB-A317 – a PD-1 inhibitor from Beigene. Celgene paid US$263 M upfront to gain exclusive rights to BGB-A317 in the US, EU, Japan and rest of the world excluding Asia for solid tumour indications. Celgene also acquired a 5.9% equity stake in Beigene. Beigene could be eligible for up to US$980 M in milestones and royalties and retains rights for BGB-A317 in solid cancers in Asian territories outside Japan and haematological cancers globally, as well as the acquisition of Celgene’s commercial infrastructure in China. In addition, Beigene also gains exclusive Chinese rights to market Celgene’s Abraxane®, Revlimid®, Vidaza® and Phase I candidate CC-122 in the transaction.